@FierceBiotech: Novartis takes the transparency 'pledge,' but is it too little, too late? More | Follow @FierceBiotech
@JohnCFierce: Are Lilly and J&J on the short list? Mystery U.S. pharma company circles Andromeda and its PhIII diabetes drug. Story | Follow @JohnCFierce
@DamianFierce: With a reported $330M+ on the way, Abingworth is the latest biotech VC amassing a new fund. News | Follow @DamianFierce
@EmilyMFierce: Trending at FierceBiotechResearch.com --> Scientist: Let's not discredit acid-bath stem cell studies--yet. More | Follow @EmilyMFierce
> The EC has approved Galderma's Mirvaso for facial redness associated with rosacea. The company, which has been undergoing a restructuring, won FDA approval for the therapy last year. Release
> Neurocrine Biosciences ($NBIX) is planning to raise about $126 million in a follow-on offering. A few weeks ago the company saw its shares rocket up on the successful conclusion of a Phase IIb study Release
> The news that Dara BioSciences won orphan drug status at the FDA sent its stock up yesterday. Story
@FierceMedDev: Foundation Medicine ended its first (partial) year as a public company revenue still heading higher. Release | Follow @FierceMedDev
@MarkHFierce: In the (marathon) battle to overturn the device tax, word from a pediatric device company CEO might help. More | Follow @MarkHFierce
@MichaelGFierce: FDA panel moves to ease iontophoresis delivery regulations to reflect modern advances. News | Follow @MichaelGFierce
@EmilyWFierce: Seno Medical Instruments raises $39M in a critical funding round for breast cancer dx device. More | Follow @EmilyWFierce
@GalenMoore: FDA may have gone too far, reading personal emails of medtech approval whistleblowers. Story | Follow @GalenMoore
> Qiagen has unveiled a low-tech HPV test in India. Piece
> A pediatric device company CEO speaks out against the device tax. More
Pharma News
@FiercePharma: GSK's new respiratory launches will give its revamped sales model a workout - FP. Story | Follow @FiercePharma
@TracyStaton: ICYMI: Thumbs up or down on megamergers? Depends on your point of view. More | Follow @TracyStaton
@EricPFierce: No sooner does Commish Hamburg return from India than the FDA reveals a new warning letter about data faking there. News | Follow @EricPFierce
@CarlyHFierce: Yesterday's best-read on FP: Activists urge FDA to slap black-box warnings on lucrative testosterone boosters. Article | Follow @CarlyHFierce
> Pharma fights back against proposed changes to Medicare drug spending. Piece
> Boehringer Ingelheim withheld Pradaxa data from FDA, lawsuit files show. News
> Pharma shelled out $3.75B in fraud penalties in record-setting year, feds say. Story
Diagnostics News
> Daktari Diagnostics is raising up to $30M to support its Africa HIV test launch. Story
> Loyola team zeros in on an early-stage heart attack biomarker. Research
> Diagnostic Biochips is pursuing angel funding for a microchip brain implant. News
> A massive review reaffirms fecal test's place in colon cancer Dx. Article
> Tumor DNA can serve as noninvasive biomarker to stage and help treat cancer. Article
> Ezose Sciences will explore glycans as a possible Parkinson's biomarker. Brief
Drug Delivery News
> Clustered nanoparticles deliver chemo to fight drug-resistant ovarian cancer. News
> Inner-ear delivery device sends drugs out, draws fluid in. More
> FDA panel moves to ease iontophoresis delivery regulations to reflect modern advances. Story
> Teva snags an EU recommendation for its asthma, COPD inhaler. Article
> Single microparticle holds 3 different drugs for a cancer 1-2-3 punch. Piece
> Nanoparticles deliver chemotherapy when hit with a targeted light. Item
Pharma Marketing News
> Lilly's dulaglutide matches Victoza in study, but the real loser is AstraZeneca's Bydureon. Analysis
> Endo's off-label Lidoderm mantra, whistleblower says: 'Put the patch where the pain is.' Story
> GSK's new respiratory launches will give its revamped sales model a workout. News
> Even for busy doctors, 'nothing is as good as a rep' for getting pharma info. Article
> Amarin's future dims further as FDA nixes 5-year Vascepa exclusivity. Story
> Eisai's revved-up Belviq marketing starting to pay off, analysts say. Story
> Thrombogenics is 'exploring options' to jump-start Jetrea sales. Marketing partner, perhaps? Brief